key: cord-0790406-hwb1afl3
authors: Innis, B. L.; Mercer, L. D.; White, J. A.; Scharf, R.; Hjorth, R.; Lamola, S.; Raghunandan, R.; Lal, M.; McLellan, J. S.; Hsieh, C.-L.; Pitisuttithum, P.; Luvira, V.; Muangnoicharoen, S.; Lawpoolsri, S.; Sivakorn, C.; Phumratanaprapin, W.; Kamolratanakul, S.; Phonrat, B.; Sabmee, Y.; Thantamnu, N.; Wirachwong, P.; Poopipatpol, K.; Surichan, S.; Prangpratanporn, S.; Kaweepornpoj, R.; Theerasurakarn, S.; Narakorn, P.; Singchareon, R.; Suthepakul, N.; Puksuriwong, S.; Vilasmongkolchai, T.; Gagnon, L.; Tran, S.; Khan, S.; Krammer, F.; Mena, I.; Garcia-Sastre, A.; Sun, W.; Liu, Y.; McCroskery, S.
title: Safety and Immunogenicity of an Inactivated Recombinant Newcastle Disease Virus Vaccine Expressing SARS-CoV-2 Spike: Interim Results of a Randomised, Placebo-Controlled, Phase 1/2 Trial
date: 2021-09-20
journal: medRxiv : the preprint server for health sciences
DOI: 10.1101/2021.09.17.21263758
sha: 726315945eb2e2fadc8f3a82c29fd34bacd76111
doc_id: 790406
cord_uid: hwb1afl3

Production of affordable coronavirus disease 2019 (COVID-19) vaccines in low- and middle-income countries is needed. NDV-HXP-S is an inactivated egg-based Newcastle disease virus vaccine expressing the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It is being developed in Thailand, Vietnam, and Brazil; herein are initial results from Thailand. This phase 1 stage of a randomised, dose-escalation, observer-blind, placebo-controlled, phase 1/2 trial was conducted at the Vaccine Trial Centre, Mahidol University (Bangkok). Healthy adults aged 18-59 years, non-pregnant and negative for SARS-CoV-2 antibodies were eligible. Participants were block randomised to receive one of six treatments by intramuscular injection twice, 28 days apart: 1 microgram (mcg) +/- CpG1018 (a toll-like receptor 9 agonist), 3 mcg +/- CpG1018, 10 mcg, or placebo. Participants and personnel assessing outcomes were masked to treatment. The primary outcomes were solicited and spontaneously reported adverse events (AEs) during 7 and 28 days after each vaccination, respectively. Secondary outcomes were immunogenicity measures (anti-S IgG and pseudotyped virus neutralisation). An interim analysis assessed safety at day 57 in treatment-exposed individuals and immunogenicity through day 43 per protocol. ClinicalTrials.gov (NCT04764422). Between March 20 and April 23, 2021, 377 individuals were screened and 210 were enrolled (35 per group); all received dose one; five missed dose two. The most common solicited AEs among vaccinees, all predominantly mild, were injection site pain (<63%), fatigue (<35%), headache (<32%), and myalgia (<32%). The proportion reporting a vaccine-related AE ranged from 5.7% to 17.1% among vaccine groups and was 2.9% in controls; there was no vaccine-related serious adverse event. The immunogenicity of the 10 mcg formulation ranked best, followed by 3 mcg+CpG1018, 3 mcg, 1 mcg+CpG1018, and 1 mcg formulations. On day 43, the geometric mean concentrations of 50% neutralising antibody ranged from 122.23 IU/mL (1 mcg, 95% CI 86.40-172.91) to 474.35 IU/mL (10 mcg, 95% CI 320.90-701.19), with 93.9% to 100% of vaccine groups attaining a => 4-fold increase over baseline. NDV-HXP-S had an acceptable safety profile and potent immunogenicity. The 3 mcg and 3 mcg+CpG1018 formulations advanced to phase 2.

There remains a shocking imbalance in the global distribution of coronavirus disease 2019 (COVID-19) 76 vaccines. 1 To achieve control of the COVID-19 pandemic in low-and middle-income countries (LMICs) 77

where most of the global population resides, there must be a great increase in sustainable supply of 78 affordable vaccines. The manufacturing capacity for egg-based inactivated influenza vaccines (IIV) is 79 among the largest in the world; these facilities, some in middle-income countries and operating for less 80 than six months per year, use locally produced embryonated eggs to make more than a billion doses 81 annually of affordable human vaccines. 2 To enable these manufacturers to respond to the COVID-19 82 pandemic, we developed a COVID-19 vaccine for production in eggs, based on a Newcastle disease virus 83 (NDV) expressing the ectodomain of a novel membrane-anchored, prefusion-stabilized severe acute 84 respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein construct, wherein virions are purified 85 and inactivated (NDV-HXP-S). 3-5 86

From September to November 2020, manufacturers in Thailand, Vietnam, and Brazil modified their IIV 87 manufacturing process to optimize production of beta-propiolactone (BPL)-inactivated NDV-HXP-S, 88

achieving high yields at pilot scale; the result was three similar processes. A preclinical evaluation of 89 their vaccine candidates, formulated with and without CpG1018, a toll-like receptor 9 agonist adjuvant 90 (Dynavax Technologies) 6 confirmed that they were highly immunogenic and protective in hamsters 5 with 91 no sign of toxicity in rats at the maximum human doses planned for evaluation (3 µg S protein+1·5 mg 92 CpG1018; 10 µg S protein). These results enabled all three manufacturers to initiate clinical 93 development of their vaccine candidates. Herein, we report interim safety and immunogenicity data 94 generated in the phase 1 portion of an adaptive phase 1/2 clinical trial evaluating the NDV-HXP-S 95 vaccine candidate developed by The Government Pharmaceutical Organization of Thailand (GPO). These 96 results provide the first evidence in humans that the NDV vector technology expressing a six-proline 97 prefusion-stabilized spike protein construct offers a unique platform for affordable manufacturing of a 98 well-tolerated and highly immunogenic COVID-19 vaccine. 99

Study design and participants 101

The phase 1 segment of a randomised, observer-blind, placebo-controlled, phase 1/2 trial was 102 

Enrolled subjects were randomly assigned in sequence to one of 6 equal groups (vaccine containing 1 µg 115 S ± 1·5mg CpG1018 adjuvant, 3 µg S ± 1·5mg CpG1018 adjuvant, 10 µg S, or saline placebo). Subjects 116 were enrolled in stages, each including active treatment and placebo groups, using a computer-117 generated block randomisation sequence prepared by an independent statistician; an unblinded 118 pharmacist team dispensed each treatment according to the randomization sequence. The first 18 119 subjects (sentinel cohort) were enrolled to three sequential sentinel groups; 3:1, 1 µg and placebo; 120 3:3:1, 3 µg or 1 µg+CpG1018 and placebo; and 3:3:1, 10 µg or 3 µg+CpG1018 and placebo, After safety 121 data were reviewed for the sentinel groups, the next 192 subjects were randomised in 5-dose-cohorts; 122 32:6, 1 µg and placebo; 32:6, 3 µg and placebo; 32:6, 1 µg+CpG1018 and placebo; 32:7, 10 µg and 123 placebo; and 32:7, 3 µg+CpG1018 and placebo. All participants and personnel other than the unmasked 124 pharmacy team and vaccinators were masked to treatment. 125

Procedures 126

The recombinant NDV-HXP-S vaccine was manufactured according to current Good Manufacturing 127

Practice by the GPO in their Influenza Vaccine Plant (Saraburi, Thailand) using locally procured 128 embryonated eggs inoculated with a master virus seed made and extensively tested for adventitious 129 agents by the Icahn School of Medicine at Mount Sinai (New York, USA). After incubation for 72 hours at 130 37°C, eggs were chilled overnight at 4°C, then the allantoic fluids were harvested, clarified, and 131 concentrated. Recombinant virus particles were purified from the concentrated harvest by two 132 sequential continuous flow sucrose gradient centrifugations, diafiltered against phosphate-buffered 133 saline (PBS), inactivated by treatment with 1:4000 BPL for 24 hours at 4°C, and 0.2 micron filter-134 sterilized. Vaccine potency was measured by direct enzyme-linked immunosorbent assay (ELISA) using a 135 human monoclonal antibody (CR3022 7 ) to SARS-CoV-2 spike glycoprotein S1 (LakePharma Inc) and an 136 NDV-HXP-S standard that had been calibrated to a purified HXP-S reference 8 by sodium dodecyl sulphate 137 polyacrylamide gel electrophoresis (SDS-PAGE) densitometry. 138

Unmasked staff administered study treatments by intramuscular injection of 0·5 mL on study days 1 and 139 29. Blood samples were drawn and clinical assessments were done for safety and immunogenicity 140 endpoints before vaccination on days 1 (dose one), 8, 29 (dose two), 36, and 43; a clinical assessment 141 for safety only on day 57 was the last timepoint considered for this interim analysis of the phase 1 142 All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted September 20, 2021. ; https://doi.org/10.1101/2021.09.17.21263758 doi: medRxiv preprint cohort, although there will be additional immunogenicity and safety assessments on study days 197 and 143 365. Subjects were observed in the clinic for 30 minutes after each vaccination and were asked to record 144 any adverse events using paper diary cards during the 7-days after each vaccination. Subjects randomly 145 allocated to a cell-mediated immunity subset (N=12 per 10 µg, 3 µg+CpG1018, and placebo groups) had 146 additional blood collected on days 1 and 43 for isolation of peripheral blood mononuclear cells (PBMCs); 147 these were stored in liquid nitrogen until analysed. 148

Solicited injection site reactions (pain, tenderness, swelling, induration, erythema) and systemic 149 symptoms (headache, fatigue, malaise, myalgia, arthralgia, nausea, vomiting, and fever defined as oral 150 temperature ≥38°C) were recorded by subjects in a diary card that included intensity, then reported by 151 the investigators; these events were not assessed for causality. Subjects also recorded spontaneously 152 reported adverse events (AEs) for 28 days; the investigator reported these after grading them for 153 intensity and categorizing them as serious or not. The investigator also identified the following AEs of 154 special interest: potential immune-mediated medical conditions (PIMMCs), and AEs of special interest 155 associated with COVID-19. Intensity of AEs was graded 1-4 as follows: 1 or mild (minimal interference 156 with daily activities), 2 or moderate (interferes with but does not prevent daily activities), 3 or severe 157 (prevents daily activities, intervention required), and 4 or very severe (medical intervention required to 158 prevent disability or death We measured total anti-SARS-CoV-2 spike (S) IgG using a validated indirect ELISA at Nexelis (Laval, 165 Canada). Purified recombinant SARS-CoV-2 pre-fusion spike (Nexelis) at 1µg/ml in phosphate buffered 166 saline (PBS, Wisent Bioproducts) was adsorbed to 96 well Nunc Maxisorb microplates (Thermo Fischer 167 Scientific) and blocked with 5% skim milk in PBS, containing 0·05% Tween 20. Serial dilutions of test 168 samples and the assay standard plus controls were added in the plates and incubated for 60 minutes at 169 room temperature (15-30°C). After washing, horseradish peroxidase (HRP) enzyme-conjugated goat 170 anti-human IgG-Fc (Jackson ImmunoResearch Laboratories) was added for 60 minutes at room 171 temperature (15-30°C), then washed. Bound secondary antibody was reacted with 3,3′,5,5′-172 tetramethylbenzidine (TMB) ELISA peroxidase substrate (Bio-Rad Laboratories) and incubated for 30 173 minutes at room temperature (15-30°C) before the reaction was stopped with 2N H2SO4. Plates were 174 read at 450 nm with a correction at 620 nm to assess the level of anti-S IgG bound in the microtiter 175 plate. A reference standard on each plate determined the quantity of anti-S IgG in arbitrary units 176 (ELU/mL). Concentrations were transformed to binding antibody units per mL (BAU/mL), based on the 177 WHO International Standard for anti-SARS-CoV-2 immunoglobulin, 9 using a conversion factor 178 determined during assay validation (1/7·9815). The assay's cut-off and lower limit of quantitation (LLOQ) 179 was 6·3 BAU/mL. 180

We measured serum neutralising activity against the Wuhan strain of SARS-CoV-2 in a validated 181 pseudotyped virus neutralisation assay (PNA) that assessed particle entry-inhibition. 10 Briefly, 182 pseudotyped virus particles containing a luciferase reporter for detection were made from a modified 183 vesicular stomatitis virus (VSVΔG) backbone expressing the full-length spike glycoprotein of SARS-CoV-2 184 (MN908947, Wuhan-Hu-1) from which the last 19 amino acids of the cytoplasmic tail were removed. 11 185 Seven two-fold serial dilutions of heat-inactivated serum samples were prepared in 96-well round-186 bottom transfer plates (Corning). Pseudotyped virus was added to the serum dilutions at a target 187 All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. immunoglobulin, using a conversion factor determined during assay validation (1/1,872). The assay's 197 cut-off and LLOQ were 5·3 IU/mL (10 as NT50) and 5.9 IU/mL, respectively. To benchmark vaccine 198 immunogenicity assessed in BAU/mL and IU/mL, we used a panel of human convalescent serum samples 199 (HCS) collected 14 days after symptom onset from consecutive cases of mild to moderate COVID-19 200 illness among health care personnel seen as outpatients in Quebec, Canada during mid-2020. We also 201 calculated 80% neutralisation titres (NT80); nevertheless, as the PNA was not validated for this 202 measurement, these results are not presented. We used the same PNA assay to measure NT50 (reported 203 as titres) against pseudotyped virus particles generated for SARS-CoV-2 variants of concern B.1.315 12 204 and P.1 13 . In the absence of positive controls for the variant strains of SARS-CoV-2, we used control sera 205 for the Wuhan-Hu-1 strain. 206

To assess cellular immunity, we quantified interferon-γ (IFN-γ) and IL-5 producing cells in PBMCs 207 stimulated with SARS-CoV-2 spike peptide pools (vial 1 158 overlapping peptides, vial 2 157 overlapping 208 peptides; JPT Peptide) using a human IFN-γ/IL-5 double-colour ELISpot kit (Cellular Technologies) in a 209 qualified assay. Briefly, activated 96-well plates were coated with anti-human IFN-γ/IL-5 capture 210 antibodies at 2-8°C. Following overnight (>16h) coating, plates were washed with PBS, and stimulation 211 media containing SARS-CoV-2 peptide pool 1 or peptide pool 2 or control media was added to wells, 212 followed by the addition of PBMCs at 2x10 5 cells/well. After an approximately 44-hour incubation at 213 37 o C±1°C with 5% CO2, plates were washed to remove cells from the wells. Anti-human IFN-γ/IL-5 214 detection solution (containing anti-human IFN-γ fluorescein isothiocyanate [FITC] and anti-human IL-5 215

[biotin] detection antibodies) was then added to the wells and incubated at room temperature (15-30°C) 216

for 2 h ± 10min to detect IFN-γ and IL-5 cytokine captured on the bottom of the well. Plates were 217 washed, followed by the addition of a tertiary solution (containing FITC-HRP and streptavidin-alkaline 218 phosphatase). Following incubation with the tertiary solution, plates were washed, and blue and red 219 developer solutions were added in sequence (with washes in between), resulting in the appearance of 220 blue (for IL-5) and red (for IFN-γ) spot forming units (SFUs) in proportion to T cell activity. SFUs were 221 counted by an ImmunoSpot CTL Analyzer (using CTL ImmunoCapture Software (v7·0·14·0) and CTL 222 ImmunoSpot Professional DC Analyzer (v7·0·28·2)). Readouts (one per peptide pool for IFN-γ, one per 223 peptide pool for IL-5) were expressed as number of SFU/10 6 cells and combined as a ratio. The assay's 224 LLOQ for IFN-γ was 109 SFU/10 6 cells and for IL-5 was 43 SFU/10 6 cells. 225

Outcome 226

The primary outcomes were frequency and intensity of solicited injection site and systemic AEs during 7 227 days after vaccination; frequency, intensity, and relatedness of clinically significant haematological and 228 biochemical measurements at 7 days after each vaccination; frequency, intensity, and relatedness of 229 unsolicited AEs during 28 days after each vaccination; and occurrence of medically-attended AEs, serious 230

AEs, and AEs of special interest during the interim analysis period of 57 days after-first vaccination. The 231 secondary immunogenicity outcomes were anti-S IgG and NT50 against Wuhan-1 strain SARS-CoV-2 232 pseudotyped virus assessed on days 29 and 43 and expressed as geometric mean titre (GMT) or 233 All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted September 20, 2021. ; https://doi.org/10.1101/2021.09.17.21263758 doi: medRxiv preprint concentration (GMCs, BAU/mL for ELISA, or IU/mL for PNA), geometric mean fold rise (GMFR) from 234 baseline, and percentage of subjects with ≥4-fold increase and ≥10-fold increase from baseline. The 235 exploratory immunogenicity outcomes were cell-mediated immunity to SARS-CoV-2 S protein, measured 236 as the ratio of IFN-γ/IL-5 expressing cells on days 1 and 43 in a random subset of subjects receiving two 237 vaccine formulations (10 µg or 3 µg+CpG1018) or placebo. We also assessed NT50 GMTs and the 238 percentage of subjects with a NT50 titre ≥4-fold higher than the LLOQ (1:10 titre), against vaccine-239 heterologous SARS-CoV-2 pseudotyped virus (SARS-CoV-2 variants of concern B.1.351 and P.1) on day 240

This Phase 1/2 study (ClinicalTrial.gov NCT04764422) has a two-part selection design with group 243 elimination after the interim analysis. In the first part, 35 subjects per group were randomized across 5 244 candidate vaccine formulations and a placebo group for a total of 210 subjects. After the interim 245 analysis, two candidates were selected to advance, at which time 250 additional subjects are to be 246 randomized 2:2:1 to the two selected candidate groups and the placebo, respectively. The study was 247 designed to have greater than 90% power to identify the candidate with the highest response as 248 measured by the NT50 by ranked GMCs, assuming the true GMC is at least 1·5-fold larger than the 249 second highest candidate group and to provide a preliminary safety evaluation of the candidates. An 250 independent data monitoring committee provided safety oversight. 251

All statistical tests were two-sided with a significance level of 0·05. All statistical analyses were 252 performed by an independent statistician using SAS version 9·4. All safety assessments took place in the 253 treatment-exposed population, according to the treatment received. All subject-level percentages were 254 supplemented with two-sided 95% confidence intervals computed via the Clopper-Pearson method. The 255 analysis of immunogenicity was performed in the per protocol population, which excludes subjects with 256 All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted September 20, 2021. ; https://doi.org/10.1101/2021.09.17.21263758 doi: medRxiv preprint protocol deviations that would affect the assessment. Immunogenicity data were descriptively analysed. 257

Geometric mean antibody responses were reported by treatment and time point, accompanied by 95% 258

CIs. The analysis of geometric means excluded subjects who were seropositive at baseline (defined by 259 anti-S IgG >LLOQ as measured by ELISA). Geometric mean fold rises (GMFR) were calculated relative to 260 baseline using the log difference of the paired samples, with corresponding CIs computed via the t-261 distribution, utilizing the antilog transformation to present the ratio. The proportions of subjects with 262

GMFRs of NT50 ≥4 and ≥10 from baseline were summarized with 95% CIs. The analysis of 263 immunogenicity relative to baseline included baseline seropositive subjects. 264

The funders of the study had no role in data collection, data analysis, or writing of the statistical report. 266 GPO was the clinical trial sponsor and approved the study protocol. GPO employees contributed as 267 authors by preparing the investigational vaccine, interpreting data, and writing this report. 268 All five formulations of NDV-HXP-S were well tolerated with no dose limiting reactogenicity (Table 2) . 277

Most solicited injection site and systemic reactogenicity during 7 days after each vaccination was mild 278 and transient with no apparent difference between dose 1 and 2. The most common injection site 279 All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (table 2) were pain and tenderness; these were most frequent at the highest dose. The most 280 common systemic symptoms (table 2) were fatigue, headache, and myalgia, generally in less than one-281 third of subjects. Fever was uncommon. Adverse events occurring during 28 days after vaccination (table  282 3) and judged by the investigator to be treatment-related were infrequent (<15%) and there was no 283 treatment-related serious adverse event, nor any AE of special interest reported during the 57 day 284 assessment period. Haematology and serum chemistry laboratory readouts were assessed on day 8 285 following each vaccination; there was no clinically notable finding relative to baseline assessment. The 286 independent data monitoring committee expressed no safety concern. 287 Two doses of NDV-HXP-S were immunogenic in a formulation and dose dependent manner within the while the 1 µg+CpG1018 group had a GMC of 199·08 BAU/mL (95% CI 140·25-282·57). Among recipients 298 of the 3 µg dose, the GMC group difference appeared to be greater: 228·07 BAU/mL (no adjuvant, 95% 299 CI 154·22-337·27) in contrast to 356·83 BAU/mL (CpG1018, 95% CI (265·89-478·88). GMCs of anti-S IgG 300 among the vaccine groups on day 43 exceeded the GMC of the HCS panel (N=29, 72·93 95% CI 33.00-301 161.14) by 2-6-fold (table 4) . 302

All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Functional antibody responses were assessed by PNA. Low NT50 GMCs were detected in all vaccine 303 groups after the first vaccination (between 7·49 IU/mL and 12·82 IU/mL) with ≥4-fold rises in 8·8% to 304 25·7% of the vaccine groups ( figure 2B ,2D) . The second vaccine dose strongly boosted neutralisation 305

GMCs to between 122·23 IU/mL (1 µg, 95% CI 86·40-172·91) and 474·35 IU/mL (10 µg, 95% CI 320·90-306 701·19), with a ≥4-fold increase over baseline in 93·9% to 100% of vaccine groups and a ≥10-fold rise in 307 most individuals (100% in the 10 µg group, and between 79·4% and 93·9% in the remaining groups). The 308 differences in post-second dose GMCs between the unadjuvanted and adjuvanted 1 µg and 3 µg groups 309 were uncertain: 1 µg, 122·23 IU/mL (95% CI 86·40-172·91) versus 1 µg+CpG1018, 127·92 IU/mL (95% CI (table 4) . 319

Additionally, neutralisation of variant viruses was assessed by PNA on day 43. The proportion of subjects 320 attaining a day 43 NT50 titre ≥40 increased with higher doses of antigen but the incremental changes in 321 GMT were small. Reduction in neutralising potency, relative to anti-Wuhan neutralising potency, was 322 modest for the P.1 variant (2·8 to 5·3-fold) but greater for the B·1·351 variant (7·41 to 20·43-fold) (figure 323 4, table 5). In groups receiving 3 µg or 10 µg antigen doses, the proportion attaining a NT50 titre ≥40 324 ranged from 80·0% to 94·9% against P.1 and from 43·3% to 58·5% against B.1.351 (table 5) . Finally, we 325 All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted September 20, 2021. ; https://doi.org/10.1101/2021.09.17.21263758 doi: medRxiv preprint also explored T cell responses to determine if the vaccine induced primarily a type 1 (TH1) or type 2 (TH2) 326 T-helper cell response. In the small subset of subjects evaluated 14 days after a second dose, the IFN-327 γ/IL-5 ratio was strongly skewed to a TH1 response relative to pre-vaccination baseline ( and has immunogenicity that supports its potential clinical benefit. We evaluated a range of vaccine 338 doses (1 µg, 3 µg, 10 µg) having potency quantified as µg of virus envelope-anchored SARS-CoV-2 spike 339 protein; the low and medium antigen doses were evaluated in formulations with and without the TLR-9 340 agonist CpG1018 as a vaccine adjuvant. Over 28 days after each vaccine dose, all formulations were very 341 well-tolerated with little solicited injection site or systemic reactogenicity aside from mild injection site 342 pain and tenderness. There was no safety signal issuing from this early interim analysis of the clinical 343 trial. Moreover, the vaccine was strongly immunogenic in a formulation and dose dependent manner, 344 inducing levels of vaccine-homologous anti-S IgG and virus neutralising antibodies that exceeded by 345 several fold the levels measured in 14-day convalescent sera from consecutive cases of health care 346 workers with mild to moderate COVID-19 illness in 2020. Notably, the adjuvant benefit as measured by 347 enhanced induction of humoral immunity was uncertain, as the small sample size limited precision. On 348 the other hand, the vaccine at all dose levels elicited neutralising antibodies against two variants of 349 All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted September 20, 2021. ; https://doi.org/10.1101/2021.09.17.21263758 doi: medRxiv preprint concern, B.1.351 and P.1. While neutralising antibody titres decreased modestly against P.1 and more 350 markedly against B.1.351, this was expected and in the range observed with sera from recipients of the 351 mRNA vaccines BNT162b2 and mRNA-1273. 14-17 The degree of reduction in neutralisation is dependent 352 on the assay used and can be especially dramatic with pseudotyped particle inhibition assays as used in 353 this study. 14,17 Notably, the B.1.351 variant is currently regarded as a worst case example of immune 354 evasion; accordingly, the NDV-HXP-S would be predicted to have neutralising activity against the now 355 prevalent delta (B.1.617.2) variant. The T cell response assessed showed a bias towards a TH1 response 356 in both evaluated dose groups, alleviating concerns about enhanced disease associated with a TH2 357 response (as observed with SARS-CoV-1 in some animal models 18 ). These initial data, while sparse, 358

suggest the vaccine-induced T cell memory capable of an antiviral response. 359

The study has several limitations. The sample size per treatment group was small, limiting precision, and 360 assessments were restricted to 43 days for immunogenicity and 57 days for reactogenicity and safety, 361 narrowing our perspective to acute outcomes only. These are inherent problems of phase 1 trials and 362 interim analyses in a pandemic response setting. Nevertheless, as clinical trials with similar vaccines are 363 underway in Vietnam (NCT04830800) and Brazil (NCT04993209), we determined that publication of 364 early data is a priority. The study had strengths as well. The vaccine construct is a novel platform 365 expressing a second-generation pre-fusion stabilized S protein in a membrane-bound trimeric 366 conformation. We hypothesize that these characteristics contribute to the vaccine's notable 367 immunogenicity, even without the CpG1018 adjuvant. The anti-S ELISA and PNA used to assess vaccine-368 homologous NT50 potency were validated and results are expressed in International Units 9 for future 369 comparisons. The induction of anti-S binding and neutralising antibodies was contrasted with mean 370 levels in human convalescent serum and found to be superior, especially in the mid-and high-dose 371 groups. However, the neutralisation assay is not a live virus assay; therefore, it is presently uncertain 372 how our functional antibody readouts can be used to benchmark against live virus neutralising antibody 373 All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted September 20, 2021. ; https://doi.org/10.1101/2021.09.17.21263758 doi: medRxiv preprint levels induced by authorized or licensed vaccines. Correlation between neutralising antibody titres and 374 vaccine efficacy and individual protection has recently been shown; work is ongoing to integrate these 375 data into this analytic framework. 19-21 On the other hand, mean vaccine anti-S IgG ELISA responses 376 normalized by the mean in convalescent sera as proposed by Earle and others 19 suggest that the NDV-377 HXP-S vaccine will afford important clinical benefit. Furthermore, we plan to conduct a clinical trial in 378 which the NDV-HXP-S vaccine will be contrasted to an authorized comparator vaccine to generate 379 relative immunogenicity evidence that may be predictive of clinical benefit. 380

In summary, we show that the inactivated NDV-HXP-S vaccine candidate has an acceptable safety profile 381 and is highly immunogenic. This vaccine can be produced at low cost in any facility designed for 382 production of inactivated influenza virus vaccine; such facilities are present in a number of LMICs. 2 383

Based on these results, and acknowledging the imperative to maximize output of vaccine doses from the 384 manufacturing facility, the 3 µg and 3 µg+CpG1018 formulations were selected for further assessment in 385 the phase 2 stage of the ongoing clinical trial. 386

Word count 4,361 387 388 All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Under review, to be decided by the sponsor prior to publication. 409 410 All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted September 20, 2021. ; https://doi.org/10.1101/2021.09.17.21263758 doi: medRxiv preprint Table 1 . Baseline characteristics of the exposed population 477 Data are median (q1-q3) or n (%) 478 479 All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Dose 2 0 (0·0%) 0 (0·0%) 0 (0·0%) 0 (0·0%) 0 (0·0%) 0 (0·0%) All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. * Serious AE was reported by one subject only who remains masked (0·5%, 95% CI 0·0-2·6) 485 486 All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted September 20, 2021. ; https://doi.org/10.1101/2021.09.17.21263758 doi: medRxiv preprint Table 5 . GMT and percentage of subjects with a ≥4-fold rise from baseline (day 43) for NT50 by PNA 491

against Wuhan strain and variants of concern 492 1 µg S 1 µg S+CpG 3 µg S 3 µg S+CpG 10 µg S Placebo 493 All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted September 20, 2021. ; https://doi.org/10.1101/2021.09.17.21263758 doi: medRxiv preprint preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted September 20, 2021. ; https://doi.org/10.1101/2021.09.17.21263758 doi: medRxiv preprint 519 All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted September 20, 2021. ; https://doi.org/10.1101/2021.09.17.21263758 doi: medRxiv preprint 520 521 All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted September 20, 2021. ; https://doi.org/10.1101/2021.09.17.21263758 doi: medRxiv preprint

Global production capacity of seasonal and pandemic 434 influenza vaccines in 2019

A Newcastle Disease Virus (NDV) Expressing a Membrane-436

Anchored Spike as a Cost-Effective Inactivated SARS-CoV-2 Vaccine

Structure-based design of prefusion

CoV-2 spikes

A Newcastle disease virus-vector expressing a prefusion-stabilized 440 spike protein of SARS-CoV-2 induces protective immune responses against prototype virus and variants 441 of concern in mice and hamsters

Development of the CpG Adjuvant 1018: A Case Study

Human monoclonal antibody combination against 445 SARS coronavirus: synergy and coverage of escape mutants

Structure-based design of prefusion

CoV-2 spikes

WHO International Standard for anti-SARS-CoV-2 449 immunoglobulin

Quantification of SARS-CoV-2 . neutralising antibody by 451 wild-type plaque reduction neutralisation, microneutralisation and pseudotyped virus neutralisation 452 assays

SARS-CoV-2 Spike Alterations Enhance

Pseudoparticle Titers and Replication-Competent VSV-SARS-CoV-2 Virus

Detection of a SARS-CoV-2 variant of concern in 456 South Africa

Genomics and epidemiology of the P.1 SARS-CoV-2 458 lineage in Manaus, Brazil

Reduced . neutralising activity of post-SARS-CoV-2 462 vaccination serum against variants B.1.617.2, B.1.351, B.1.1.7+E484K and a sub-variant of C.37

Neutralisation of SARS-CoV-2 Variants B.1.429 and B.1.351. N Engl 467

SARS-CoV-2 vaccines in development

Evidence for antibody as a protective correlate 470 for COVID-19 vaccines

neutralising antibody levels are highly predictive of 472 immune protection from symptomatic SARS-CoV-2 infection

Immune Correlates Analysis of the mRNA-1273

All rights reserved. No reuse allowed without permission

preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity